Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 6, 2000, Pages 298-303

  Muck W ^a   Frey, R ^a   Unger, S ^a   Voith, B ^a  

^a BAYER AG   (Germany)

Author keywords

Bioavailability; Cerivastatin; Food effect; HMG CoA reductase inhibitor; Hypercholesterolemia; Statins

Indexed keywords

CERIVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG TOLERABILITY; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0343569870     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38298     Document Type: Article

References (18)

1. Appel S, Dingemanse J 1996 Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 32: 39-55
2. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ 1996 Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 36: 604-609
3. Davignon J, Hanefeld M, Nakaya N, Hunninghake DB, lnsull W Jr, Ose L 1998 Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol 82: 32J-39J
4. Dobrinska MR, Stubbs RJ, Gregg MH, Schwartz MS, Hessey GA, Till AE 1988 Effects of dose and food on HMG-CoA reductase inhibitor profiles after lovastatin (Mevacor). Pharm Res 5 (Suppl): S182
5. Dujovne CA, Davidson MH 1994 Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety and efficacy. Am J Med 96 (Suppl 6A): 37-40
6. Food and Drug Administration 1997 Draft Guidance for Industry: Food-effect Bioavailability and Bioequivalence Studies. Food and Drug Administration (FDA), Rockville, MD
7. Gibaldi M, Perrier D 1980 Pharmacokinetics. Marcel Dekker, New York
8. Insull W, Stein E, Whalen E, Ripa S and the Cerivastatin Study Group 1997 Cerivastatin: a new potent HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolemia. J Am Coll Cardiol 29: 46A
9. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH et al 1996 Dietary guidelines for healthy American adults. Circulation 94: 1795-1800
10. Krol GJ, Beck GW, Ritter W, Lettieri JT 1993 LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
11. Mazzu A, Lettieri J, Heller AH 1997 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Atherosclerosis 130 (Suppl): S29
12. Wück W, Ochmann K, Mazzu A, Lettieri J 1999 Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor. J Int Med Res 27: 20-27
13. Pan HY, De Vault AR, Brescia D, Willard, DA. McGovern ME, Whigan DB et al 1993 Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 31: 291-294
14. Parker TS, McNamara DJ, Brown C, Garrigan O, Kolb R, Batwin H el al 1982 Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 79: 3037-3041
15. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EH Jr, Alberts AW et al 1984 Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 74: 795-804
16. Radulovic LL, Cilla DD, Posnar EL, Sedman AJ, Whitfield LR 1995 Effect of food on the bioavailability of atorvastatin, an UMG-CoA reductase inhibitor. J Clin Pharmacol 35: 990-994
17. Stein E 1998 Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Atherosclerosis 139 (Suppl 1): S15-22
18. Stein E, Sprecher DL, Allenby KS, Tosiello R, Whaler, E, Ripa SR et al 1997 Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg/day in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 2: 7-16